These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 11812056)
1. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'. Montalescot G Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056 [No Abstract] [Full Text] [Related]
2. Comparison of angioplasty with stenting in acute myocardial infarction. Herrmann HC N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478 [No Abstract] [Full Text] [Related]
3. Platelet GP IIb/IIIa inhibition in myocardial infarction treated by coronary stenting: ready for prime time. Anderson HV J Invasive Cardiol; 2000 Mar; 12(3):140-1. PubMed ID: 10877555 [No Abstract] [Full Text] [Related]
7. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI? Gilchrist IC Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396 [No Abstract] [Full Text] [Related]
8. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies]. Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692 [No Abstract] [Full Text] [Related]
9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
11. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
13. Glycoprotein IIb/IIIa antagonists: an attractive new approach to reperfusion in acute myocardial infarction. Gambhir DS Indian Heart J; 1999; 51(3):259-60, 309. PubMed ID: 10624062 [No Abstract] [Full Text] [Related]
14. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Kereiakes DJ Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889 [TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role? Mukherjee D; Roffi M J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343 [No Abstract] [Full Text] [Related]
16. [Glycoprotein IIb/IIIa blockers. Their usefulness in current cardiovascular therapeutics]. López Cuéllar J Arch Inst Cardiol Mex; 1999; 69(3):272-81. PubMed ID: 10529862 [No Abstract] [Full Text] [Related]
17. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158 [No Abstract] [Full Text] [Related]
18. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention? Cole JH; Weintraub WS Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689 [No Abstract] [Full Text] [Related]
19. The TARGET trial: hit or miss? Moliterno DJ; Topol EJ Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001 [No Abstract] [Full Text] [Related]